Search research articles
Contact Us
Filters
Showing results (51-60 of 144) with videos related to
Page
of 15
Sort By:
Clinical Genitourinary Cancer
|
September 4, 2017
Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer
Aditya Bagrodia, Ranjit Sukhu, Andrew G Winer, et al.
The Journal of Clinical Investigation
|
August 19, 2025
Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer
Judit Börcsök, Diyavarshini Gopaul, Daphne Devesa-Serrano, et al.
European Urology Open Science
|
April 21, 2025
Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance)
Brendan J Guercio, Karissa Whiting, Ronak H Shah, et al.
BJU International
|
April 18, 2021
Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy
Nima Almassi, Emily A Vertosick, Daniel D Sjoberg, et al.
JCO Oncology Practice
|
June 16, 2025
Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer Research
Michal Sternschuss, Michael Lattanzi, Emily Vertosick, et al.
BJU International
|
April 5, 2013
Phase II study of everolimus in metastatic urothelial cancer
Matthew I Milowsky, Gopa Iyer, Ashley M Regazzi, et al.
Cancer Chemotherapy and Pharmacology
|
November 30, 2011
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors
Gopa Iyer, Michael J Morris, Dana Rathkopf, et al.
Cancer Medicine
|
December 31, 2020
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract
Michal Sarfaty, Karissa Whiting, Min Yuen Teo, et al.
The Journal of Pathology
|
May 7, 2011
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma
Hikmat A Al-Ahmadie, Gopa Iyer, Manickam Janakiraman, et al.
European Urology
|
June 7, 2017
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets
Eugene J Pietzak, Aditya Bagrodia, Eugene K Cha, et al.
Page
of 15
Search research articles
Search
Showing results (51-60 of 144) with videos related to
Sort By:
Page
of 15
Clinical Genitourinary Cancer
|
September 4, 2017
Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer
Aditya Bagrodia, Ranjit Sukhu, Andrew G Winer, et al.
The Journal of Clinical Investigation
|
August 19, 2025
Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer
Judit Börcsök, Diyavarshini Gopaul, Daphne Devesa-Serrano, et al.
European Urology Open Science
|
April 21, 2025
Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance)
Brendan J Guercio, Karissa Whiting, Ronak H Shah, et al.
BJU International
|
April 18, 2021
Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy
Nima Almassi, Emily A Vertosick, Daniel D Sjoberg, et al.
JCO Oncology Practice
|
June 16, 2025
Quality of Informed Consent via Telemedicine Compared With In-Person for Clinical Cancer Research
Michal Sternschuss, Michael Lattanzi, Emily Vertosick, et al.
BJU International
|
April 5, 2013
Phase II study of everolimus in metastatic urothelial cancer
Matthew I Milowsky, Gopa Iyer, Ashley M Regazzi, et al.
Cancer Chemotherapy and Pharmacology
|
November 30, 2011
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors
Gopa Iyer, Michael J Morris, Dana Rathkopf, et al.
Cancer Medicine
|
December 31, 2020
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract
Michal Sarfaty, Karissa Whiting, Min Yuen Teo, et al.
The Journal of Pathology
|
May 7, 2011
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma
Hikmat A Al-Ahmadie, Gopa Iyer, Manickam Janakiraman, et al.
European Urology
|
June 7, 2017
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets
Eugene J Pietzak, Aditya Bagrodia, Eugene K Cha, et al.
Page
of 15